AstraZeneca
Cerovive failure another blow for AstraZeneca
October 26, 2006Research and Development, Sales and Marketing AstraZeneca, Cerovive, neuroscience
A drug which had held out the promise of reducing the disabling effects of stroke on patients will be abandoned …
AstraZeneca abandons diabetes drug over safety concerns
May 5, 2006Research and Development AstraZeneca, PPAR agonist
AstraZeneca is to abandon its late-stage diabetes drug Galida after new results raised doubts about its safety.Galida is a PPAR …
AstraZeneca doubles trial size for stroke drug
December 13, 2005Research and Development AstraZeneca, stroke
Late stage clinical trials of AstraZeneca’s new stroke treatment have resumed after the company decided to double the number of …
R&D Scoreboard poor gauge of pharma investment in the UK
November 8, 2005Research and Development AstraZeneca, GSK, Pfizer, R&D, R&D scoreboard
The R&D Scoreboard is fundamentally flawed as a measure of R&D investment in the UK and pharmaceutical companies are continuing …
Faslodex launched in UK
May 19, 2004AstraZeneca, Faslodex
The latest addition to AstraZeneca’s oncology franchise, breast cancer drug Faslodex has been launched in the UK.Licensed for the treatment …
Latest content
Five Facts about NHS and primary care
September 5, 2026
AI in pharma: From lab development to patient impact
September 5, 2026
